Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

GSK, MaRS Innovation Establish R&D Fund

by Lisa M. Jarvis
June 6, 2011 | A version of this story appeared in Volume 89, Issue 23

GlaxoSmithKline and MaRS Innovation, a Toronto-based nonprofit that commercializes intellectual property generated by local institutions, have established a new fund devoted to pulling research out of 16 Canadian academic institutions and hospitals and accelerating its translation into commercial products. The GSK-MaRS Innovation Fund will support research in drug development, diagnostics, and health care delivery technologies. The three-year partnership with GSK marks the second development fund launched by MaRS Innovation.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.